Engene reports first quarter 2024 financial results and recent corporate progress

Pivotal phase 2 legend study of eg-70 in bcg-unresponsive non-muscle invasive bladder cancer (nmibc) remains on track with interim data anticipated in mid-2024 closed a $200 million oversubscribed private financing, expected to extend cash runway into 2027 boston and montreal , march 11, 2024 /prnewswire/ - engene holdings inc. (nasdaq: engn or "engene" or the "company"), a clinical-stage genetic medicines company whose non-viral, intravesical lead product candidate, eg-70, is in a pivotal study for bcg-unresponsive non-muscle invasive bladder cancer (nmibc), today announced its financial results for the first quarter ended january 31, 2024. "this is an exciting time for the company as we move closer to realizing our vision of mainstreaming genetic medicines to address diseases with high unmet clinical needs.
ENGN Ratings Summary
ENGN Quant Ranking